Skip to main content
Premium Trial:

Request an Annual Quote

Eli, Edythe Broad Continue Support for Broad Institute with $100 Million Gift

NEW YORK (GenomeWeb News) – Eli and Edythe Broad today announced an investment of $100 million into the Broad Institute to further research into biomedical discoveries made at the institute since its inception nearly a decade ago.

Today's investment is the fourth made by the couple and brings the total amount of their contributions to $700 million. An initial investment of $100 million in 2004 launched the institute, followed by another $100 million the following year. In 2008, they pledged another $400 million to endow and establish Broad as an independent non-profit scientific research institute.

Since the institute's founding, its researchers have conducted work into human biology that includes the development and application of genomic methods leading to the discovery of genes involved in major human diseases, such as type 2 diabetes, early onset heart disease, autism, schizophrenia, inflammatory bowel disease, rheumatoid arthritis, malaria, tuberculosis, and various cancers.

During the next decade, Broad researchers plan on building on that knowledge to develop therapeutic roadmaps for human diseases.

"Their new gift will help us to use our discoveries to transform how we attack devastating disease and improve patients' lives," Eric Lander, founding director of the Broad Institute, said in a statement.

"When we made our first investment to create the Broad Institute, we shared Eric Lander’s vision that discoveries in biomedical research held the key to beating devastating disease and improving people’s lives," Eli Broad said. "As the Broad Institute nears its tenth anniversary, it has already made transformative discoveries, building on the successes of the Human Genome Project. Our latest investment is intended to catalyze the next decade of innovation and discovery."

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.